论文部分内容阅读
目的:了解肝癌患者的肝炎病毒感染状况。方法:采用酶联免疫吸附试验(ELISA)检测了肝癌、其他肿瘤及非肿瘤患者肝炎病毒感染的血清学标志。结果:在肝癌患者中乙型肝炎(HBV)HBsAg、HBeAg、抗-HBc、丙型肝炎(抗-HCV)、丁型肝炎(抗-HDV)、戊型肝炎(抗-HEV)和庚型肝炎(抗-HGV)阳性率分别为28.1%、10.7%、29.8%、13.2%、5.0%、7.4%和4.5%;其他肿瘤患者为10.1%、7.1%、12.6%、4.5%、2.0%、2.8%和2.5%;非肿瘤患者为2.5%、2.0%、3.0%、2.0%、1.5%、2.5%和2.0%。肝癌患者HBV病毒与其他肝炎病毒混合感染率为14.9%。结论:肝癌与HBV病毒感染有密切关系,其抗-HEV和抗-HDV阳性率也高于非肿瘤患者,对献血员血液及患者在输血或手术前进行肝炎病毒血清学标志的检测,是预防肝炎病毒感染和区分医患责任的重要措施。
Objective: To understand the status of hepatitis virus infection in patients with liver cancer. Methods: The serological markers of hepatitis virus infection in liver cancer, other tumors and non-tumor patients were detected by enzyme-linked immunosorbent assay (ELISA). Results: Hepatitis B virus (HBsAg), HBeAg, anti-HBc, hepatitis C (anti-HCV), hepatitis D (anti-HDV), hepatitis E (anti-HEV) and hepatitis G (Anti-HGV) were 28.1%, 10.7%, 29.8%, 13.2%, 5.0%, 7.4% and 4.5% respectively. The other tumors were 10.1%, 7.1%, 12.6%, 4.5%, 2.0% % And 2.5% respectively; non-tumor patients were 2.5%, 2.0%, 3.0%, 2.0%, 1.5%, 2.5% and 2.0%. The mixed infection rate of HBV and other hepatitis viruses in HCC patients was 14.9%. Conclusion: Hepatocarcinoma is closely related to HBV infection, and its positive rate of anti-HEV and anti-HDV is also higher than that of non-tumorous patients. The detection of hepatitis B virus serological markers in blood donors and patients before blood transfusion or surgery is a preventive measure Hepatitis virus infection and the important measure to distinguish between medical and patient responsibility.